Expert Opinion on Pharmacotherapy

Article	Citations
Oral anticoagulation therapy in the setting of liver disease	69
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook	50
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond	48
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges	44
Current treatment options for Mycobacterium marinum cutaneous infections	41
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease	38
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis	38
The pharmacological treatment and management of hyperhidrosis	35
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan	31
Pharmacotherapy developments in autophagy inhibitors for bladder cancer	29
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy	28
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis	27
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives	26
Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management	26
How have gamma-secretase inhibitors changed the treatment landscape for desmoid tumors?	26
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten	25
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy	24
Pivmecillinam: past, present, and future	24
An evaluation of ivosidenib for the treatment of IDH1-mutant cholangiocarcinoma	23
Current and emerging pharmacotherapies for the treatment of pulmonary arterial hypertension in infants	23
Pharmacologic management of ET: established therapies and emerging agents	21
When is pharmacotherapy necessary for the treatment of seasonal affective disorder?	21
Expanding indications and developmental landscape of HER2-targeted therapies in breast cancer: a pharmacotherapeutic perspective	21
Selecting optimal therapy in systemic mastocytosis: current state and future directions	21
Zanubrutinib for the treatment of chronic lymphocytic leukemia	20

Momelotinib in myelofibrosis	19
Pharmacotherapy of persistent genital arousal disorder/genito-pelvic dysesthesia: an updated review and data from a registry	19
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy	19
Potential treatments for attention-deficit/hyperactivity disorder: a focus on Phase III trials	19
How useful is chemotherapy for atypical and anaplastic meningiomas?	19
Rise and fall of decongestants in treating nasal congestion related diseases	19
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis	19
Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy	18
A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)	18
Treating pediatric aggressive behaviors and comorbid conditions	17
Pharmacotherapy of treatment-resistant hypertension in patients with chronic kidney disease	17
Current advances in colorectal cancer treatment: a review of recent clinical trials	17
An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies	17
Pharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?	17
Recent advances in the treatment of FGFR-altered cholangiocarcinoma	17
Association between clinical and laboratory factors and response to sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: a retrospective observational study	17
Correction	17
Evaluating pimavanserin tartrate as a treatment in Parkinson’s disease	16
Pharmacotherapy considerations in patients who develop acute kidney injury during anti-cancer therapy	16
Correction	16
An update on current pharmacotherapy for vulvar cancer	16
Advances in adrenergic receptors for the treatment of chronic obstructive pulmonary disease: 2023 update	16
The role of pharmacotherapy in the treatment of endometriosis: an update	16
Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature	16
Current pharmacological solutions for Behçet’s syndrome	15
Benefits and disadvantages of combination therapy with imeglimin and metformin in patients with type 2 diabetes	15
Upadacitinib in Crohn’s disease	15
Current pharmacotherapeutic strategies for Strongyloidiasis and the complications in its treatment	15
Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review	15
Looking ahead to potential incretin combination therapies for nonalcoholic steatohepatitis in patients with diabetes	15
Current advancements in pharmacotherapy for cancer cachexia	15
Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis	15
Approved medications for opioid use disorder : current update	15
Advances in the pharmacotherapeutic management of duchenne muscular dystrophy: an update	15
The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder	15
Metabolic dysfunction-associated steatohepatitis treatment: spotlight on the latest hepatoprotective drugs	15
Tirzepatide for overweight and obesity management	14
Recent progress in the use of pharmacotherapy for endometrial cancer	14
Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy	14
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors	14
Pharmacotherapy for cervical cancer: current standard of care and new perspectives	14
Tackling pulmonary fibrosis risks in post-COVID-19: cutting-edge treatments	14
Pharmacogenomics and pediatric drug development: science and political power. A narrative review	14
Modern pharmacotherapy guidance for treating alcohol use disorders	14
Simnotrelvir as a potential treatment for COVID-19	14
When is pharmacotherapy necessary for Tourette syndrome? The risks vs reward	13
Antiproliferative therapies in pulmonary arterial hypertension	13
Pharmacotherapeutic strategies for the treatment of anorexia nervosa – novel targets to break a vicious cycle	13
Optimizing drug therapy for older adults: shifting away from problematic polypharmacy	13
An evaluation of pharmacological options for Cushing’s disease: what are the state-of-the-art options?	13

Current and emerging COX inhibitors for treating postoperative pain following oral surgery	13
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia	13
Migraine in multiple sclerosis patients: potential links and treatment approach	12
Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals	12
Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper	12
Recent advances in Alzheimer’s disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein	12
A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA registry	12
Pharmacological management of pituitary adenomas – what is new on the horizon?	12
Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma	12
Evaluation of prescribing patterns of switching to and add-on lemborexant in patients treated with hypnotic medication: a nationwide claims database study in Japan	12
Response to the letter to the editor: ‘Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia’	12
An update on the currently available and emerging synthetic pharmacotherapy for uncontrolled asthma	12
Evidence-based prescribing of medications for ADHD: where are we in 2023?	12
Use of glucagon-like polypeptide 2 analogs for intestinal failure	12
Pharmacotherapy for Gastrointestinal Angiodysplasia: is it effective?	12
The relationship between cognition and the pharmacotherapy of depression	11
Current and emerging pharmacotherapies in Lennox-Gastaut syndrome	11
Perspectives on the current pharmacological strategies for chronic and atrophic gastritis: can more be done?	11
Is supplemental vitamin D useful in the clinically isolated syndrome (CIS) typical of multiple sclerosis?	11
An overview of emergency pharmacotherapy for priapism	11
Pharmacological management of gastro-esophageal reflux disease: state of the art in 2024	11
Melanoma and pediatric drug development: clinical progress vs. regulatory activism in minors - a narrative review	11
Evaluating the safety and efficacy of baricitinib for the treatment of moderate-to-severe atopic dermatitis	11
Current status of intracavernosal injection therapy in erectile dysfunction	11
Evaluating once-weekly insulin efsitora alfa for adults with type 2 diabetes	11
Pharmacological management of digital ulcers in systemic sclerosis - what is new?	11
Advances in the pharmacotherapeutic management of refractory peptic ulcers	11
Is pharmacotherapy ready to redefine the state of the art in obstructive sleep apnea care?	11
Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer?	11
Reassessing the role of aspirin in patients with coronary artery disease	11
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization	10
Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults	10
Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence	10
Time to reconsider the way of selecting antihypertensives for hypertensive left ventricular hypertrophy	10
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date	10
A comprehensive update on the pharmacological management of heterotopic ossification following hip arthroplasty: a level I evidenced based expert opinion	10
A review of pharmacokinetic data describing long-acting injectable cabotegravir during pregnancy	10
Cutting-edge pharmacotherapy for hepatitis C virus infection: a comprehensive review	10
Will elinzanetant, a neurokinin receptor antagonist, have a role in the treatment of hot flashes?	10
Auditory toxicity of antimalarials in systemic autoimmune diseases: a systematic review and critical appraisal	10
New antibiofilm strategies for the management of nontuberculous mycobacteria diseases	10
Elinzanetant, a new combined neurokinin-1/-3 receptor antagonist for the treatment of postmenopausal vasomotor symptoms	10
Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy	10
Using sequential pharmacotherapy for the treatment of osteoporosis: an update of the literature	10
The impact of age, disease severity, and vaccination status on antibiotic use in hospitalized patients with COVID-19	10
Acute severe ulcerative colitis: efficacy and safety of JAK inhibitors	10
An update on the pharmacological management of acne vulgaris: the state of the art	10
Recently approved and emerging drug options for migraine prophylaxis	10
Longitudinal efficacy of Ertugliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials	10
Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder	10
Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning	10
Risk management of medication errors: a novel conceptual framework	9
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy	9
An update on the pharmacotherapy of gout	9
Pharmacological treatment for children with constipation: present and future	9
Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder	9
Advances in the pharmacological management of acute myeloid leukemia in adults	9
Amyloidosis of the heart: pathophysiology, diagnosis, and treatment	9
Effective risk reduction strategies and pharmacological treatment for uncomplicated recurrent urinary tract infections	9
Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants	9
Clinical guidance for choosing the right pharmacotherapy for migraine attacks	9
Pharmacological management of migraine: current strategies and future directions	9
Upadacitinib in Crohn’s disease: needs more insight	9
Optimisation of direct-acting oral anticoagulants (DOACs) use for atrial fibrillation (AF) and venous thromboembolism: a practical guide	9
Addressing the long-term risks of administering antenatal steroids	9
An update on antifungal resistance in dermatophytosis	9
Update on current and emerging treatment paradigms for hyperphosphatemia in chronic kidney disease	9
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?	9
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis	9
Pharmacotherapeutic approaches to treating postpartum depression: a focus on GABA A receptor positive allosteric modulators	9
Promising therapies for the treatment of acromegaly	9
Clinical, metabolic, and immune interaction between tuberculosis and diabetes mellitus: implications and opportunities for therapies	9
The pharmacological management of treatment-resistant depression: what does the future hold?	8
Metabolic-associated steatotic liver disease and hepatocellular carcinoma	8
Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients	8
Pharmacotherapy options and drug development in bronchiectasis: spotlight on dipeptidyl-peptidase inhibitors	8
Impact of bladder cancer family history on the prognosis of patients with non-muscle invasive bladder cancer treated with Bacillus Calmette-Guerin (BCG)	8
Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature	8
GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients	8
FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions	8

Current pharmacological strategies for symptomatic reduction of persistent breathlessness – a literature review	8
Advances in pharmacotherapy for bronchiectasis in adults	8
Glasdegib for the treatment of acute myeloid leukemia	8
An evaluation of sebetralstat as the first oral on-demand therapy for Hereditary Angioedema	8
Clinical direction in the pharmacological and device management of refractory overactive bladder: the urge to develop new treatments	8
Pharmacotherapy for bipolar disorder in adults with high-functioning autism	8
Polypharmacology of carbonic anhydrase inhibitors and activators	8
Novel pharmacotherapies and breakthroughs in psoriasis treatment: 2024 and beyond	8
Navigating the liver landscape: upcoming pharmacotherapies for primary sclerosing cholangitis	8
Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?	8
Combining finerenone with SGLT-2 inhibitors: building up CONFIDENCE for the treatment of diabetic kidney disease	8
Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults	8
Pharmacotherapy in leishmaniasis: old, new treatments, their impacts and expert opinion	8
New and emerging drugs for the treatment of invasive fungal infections	8
Glucocorticoid therapy and risk of venous thromboembolism: a systematic review and meta-analysis with exploration of dose, duration, and route-specific effects	8
Pharmacological management of heart failure: a patient-centred approach	8
Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome	8
State-of-the-art and emerging antivirals for chronic hepatitis B infection	8
Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: what’s new on the horizon?	7
The pharmacological management of alcohol-related cirrhosis: what’s new?	7
Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia	7
Novel pharmacotherapy for drug-induced immune hemolytic anemia	7
Paxlovid as a potential treatment for long COVID	7
How far are we from an approved drug for nonalcoholic steatohepatitis?	7
Cardio-reno-vascular protection in type 2 diabetes mellitus: new insights into pharmacotherapeutic management	7
Current factor IX replacement options for hemophilia B and the challenges ahead	7
Oral anticoagulation with versus without antiplatelet therapy in patients with stable coronary artery disease and an indication for anticoagulation: a meta-analysis with trial sequential analysis	7
A systematic review on effect of sodium-glucose cotransporter-2 inhibitors on the metabolic and endocrinological profile of patients with polycystic ovarian syndrome	7
Liposomal drug formulations for treatment of hematological malignancies	7
Targeted small molecules in polymyalgia rheumatica: the emerging role of JAK inhibitors beyond glucocorticoids and DMARDs	7
Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma	7
What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?	7
Post-surgical pain: evolving drug treatments and challenges	7
Pharmacological management of connective tissue disease-associated pulmonary arterial hypertension	7
Current and emerging pharmacotherapy for the treatment of Lennox-Gastaut syndrome	7
Does standard pharmacotherapy still have a major role in the treatment of aggressive B-cell malignancies?	7
Essential elements for guiding patient segmentation in precision pharmacotherapy for rheumatoid arthritis: lessons up to 2025	7
Montelukast as a potential treatment for COVID-19	7
Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?	7
Venetoclax and new BCL-2 inhibitors in acute myeloid leukemia	7
Expert guidance for treating anemia in chronic kidney disease: what is the appropriate drug treatment strategy?	7
Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder	7
Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group	7
Streptozotocin in pancreatic neuroendocrine tumors: a focus on efficacy and safety	7
An overview of the current drug treatment strategies for moderate to severe, chronic malignant tumor-related pain	7
Pharmacotherapy for gastric and intestinal cramping pain: ‎ current and emerging therapies	7
Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine	6
Ivosidenib in acute myeloid leukemia	6
Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors	6
Doravirine/islatravir for the treatment of HIV	6
Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available data	6
Conditional marketing authorisation of therapeutic medicines for solid tumours in the European Union: methodological and clinical challenges	6
What are the challenges in the pharmacotherapeutic management of male genital tuberculosis?	6
BTK inhibitors in multiple sclerosis: emerging evidence and future directions	6
An evaluation of sodium zirconium cyclosilicate: a new treatment option for hyperkalaemia in China	6
Perspectives on the currently available pharmacotherapy for wet macular degeneration	6
What are the pharmacological considerations for male congenital hypogonadotropic hypogonadism?	6
Investigating cefepime/taniborbactam for the treatment of complicated urinary tract infections	6
Clinical challenges and considerations in pharmacotherapy of osteoporosis due to menopause	6
An update on the pharmacotherapy of osteoporosis	6
Selecting appropriate therapy for cutaneous T-cell lymphomas (CTCLs): recent advances and the unmet need	6
An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis	6
Recalcitrant dermatophytosis: clinicomycological features and challenges in management	6
Hereditary angioedema treatment beyond biologics: current state of preventive and on-demand approaches and new perspectives	6
Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraine	6
Valbenazine for the treatment of chorea associated with Huntington’s disease	6
New pharmacotherapies to tackle the unmet needs in bipolar disorder: a focus on acute suicidality	6
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4	6
Could protein kinase inhibitors become a next generation pharmacotherapy for non-Hodgkin’s lymphoma?	6
The first five years of SARS-CoV-2: inpatient treatment updates and future directions	6
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials	6
The current state-of-the-art in pharmacotherapy for pulmonary sarcoidosis	6
An update on inclisiran for the treatment of elevated LDL cholesterol	6
Profiling opnurasib (JDQ-443) for the treatment of non-small cell lung cancer (NSCLC)	6
Evaluating Vonoprazan for the treatment of erosive GERD and heartburn associated with GERD in adults	6
Can we effectively manage binge eating disorder with pharmacotherapy?	6
A review on pharmacological options for the treatment of erectile dysfunction: state of the art and new strategies	6
Advances in pharmacotherapy for rosacea: what is the current state of the art?	6
Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions	6
Efficacy and safety of pitolisant in children above 6 years with narcolepsy	6
New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview	6
An evaluation of the available pharmacotherapy for the treatment of hirsutism	6
Opioid MOP receptor agonists in late-stage development for the treatment of postoperative pain	6
BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes	6
Improving the treatment of Pompe disease with enzyme replacement therapy: current strategies and clinical evidence	6
A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry’s Disease	6
Highlighting advances on clinical management of pediatric HIV	5
Examining the safety and efficacy of imetelstat in low-risk myelodysplastic syndrome	5
Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer’s disease: a novel small molecule with disease modifying potential	5
Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review	5
The Park Sleep subtype in Parkinson’s disease: from concept to clinic	5
Current chemotherapeutic options for the treatment of gestational trophoblastic disease	5
Managing the neuroinflammatory pain of endometriosis in light of chronic pelvic pain	5
Expanding therapeutic options: overview of novel pharmacotherapies for dyslipidemia	5
Complicated urinary tract infections: an update of new and developing antibiotics	5